Tarsus Pharmaceuticals (TARS) Competitors $50.22 -2.01 (-3.85%) Closing price 02/14/2025 04:00 PM EasternExtended Trading$50.22 0.00 (-0.01%) As of 02/14/2025 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TARS vs. ROIV, ASND, RVMD, BPMC, LEGN, AXSM, LNTH, TLX, BBIO, and NUVLShould you be buying Tarsus Pharmaceuticals stock or one of its competitors? The main competitors of Tarsus Pharmaceuticals include Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Revolution Medicines (RVMD), Blueprint Medicines (BPMC), Legend Biotech (LEGN), Axsome Therapeutics (AXSM), Lantheus (LNTH), Telix Pharmaceuticals Limited American Depositary Shares (TLX), BridgeBio Pharma (BBIO), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry. Tarsus Pharmaceuticals vs. Roivant Sciences Ascendis Pharma A/S Revolution Medicines Blueprint Medicines Legend Biotech Axsome Therapeutics Lantheus Telix Pharmaceuticals Limited American Depositary Shares BridgeBio Pharma Nuvalent Roivant Sciences (NASDAQ:ROIV) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, community ranking, dividends and earnings. Do analysts prefer ROIV or TARS? Roivant Sciences currently has a consensus target price of $18.08, suggesting a potential upside of 71.24%. Tarsus Pharmaceuticals has a consensus target price of $56.00, suggesting a potential upside of 11.51%. Given Roivant Sciences' higher possible upside, analysts plainly believe Roivant Sciences is more favorable than Tarsus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Tarsus Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has higher valuation & earnings, ROIV or TARS? Roivant Sciences has higher revenue and earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoivant Sciences$124.79M61.60$4.35B$5.651.87Tarsus Pharmaceuticals$17.45M110.02-$135.89M-$3.81-13.18 Is ROIV or TARS more profitable? Roivant Sciences has a net margin of 3,827.42% compared to Tarsus Pharmaceuticals' net margin of -103.64%. Roivant Sciences' return on equity of -14.65% beat Tarsus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Roivant Sciences3,827.42% -14.65% -13.19% Tarsus Pharmaceuticals -103.64%-55.86%-39.28% Which has more risk & volatility, ROIV or TARS? Roivant Sciences has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Does the media favor ROIV or TARS? In the previous week, Roivant Sciences had 7 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 11 mentions for Roivant Sciences and 4 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.60 beat Roivant Sciences' score of 0.40 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Tarsus Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of ROIV or TARS? 64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 7.9% of Roivant Sciences shares are held by company insiders. Comparatively, 8.3% of Tarsus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community prefer ROIV or TARS? Roivant Sciences received 5 more outperform votes than Tarsus Pharmaceuticals when rated by MarketBeat users. Likewise, 77.94% of users gave Roivant Sciences an outperform vote while only 66.67% of users gave Tarsus Pharmaceuticals an outperform vote. CompanyUnderperformOutperformRoivant SciencesOutperform Votes5377.94% Underperform Votes1522.06% Tarsus PharmaceuticalsOutperform Votes4866.67% Underperform Votes2433.33% SummaryRoivant Sciences beats Tarsus Pharmaceuticals on 12 of the 16 factors compared between the two stocks. Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TARS vs. The Competition Export to ExcelMetricTarsus PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.92B$3.09B$5.76B$9.21BDividend YieldN/A1.67%5.27%3.99%P/E Ratio-13.1845.4825.5919.43Price / Sales110.02297.96469.2576.00Price / CashN/A192.7646.0638.90Price / Book8.444.057.305.05Net Income-$135.89M-$40.60M$3.19B$222.81M7 Day Performance-2.98%3.50%1.69%1.29%1 Month Performance7.95%4.18%4.12%1.52%1 Year Performance63.58%-10.55%22.23%16.53% Tarsus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TARSTarsus Pharmaceuticals1.3503 of 5 stars$50.22-3.8%$56.00+11.5%+63.6%$1.92B$17.45M-13.1850ROIVRoivant Sciences3.6146 of 5 stars$10.77-1.1%$17.93+66.5%-8.9%$7.84B$124.79M1.91860Earnings ReportInsider TradeGap UpASNDAscendis Pharma A/S2.4556 of 5 stars$119.47-1.2%$191.57+60.3%-7.9%$7.25B$288.08M-14.79640Earnings ReportAnalyst RevisionRVMDRevolution Medicines4.6095 of 5 stars$42.02-0.4%$66.25+57.7%+37.8%$7.07B$11.58M-11.70250Positive NewsBPMCBlueprint Medicines3.115 of 5 stars$103.88-1.0%$123.72+19.1%+4.1%$6.60B$434.42M-49.23640Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoverageLEGNLegend Biotech2.7714 of 5 stars$35.78+1.1%$79.50+122.2%-37.3%$6.53B$285.14M-37.661,800Positive NewsGap UpAXSMAxsome Therapeutics4.6482 of 5 stars$126.94+20.0%$134.00+5.6%+41.3%$6.15B$270.60M-19.44380Insider TradeHigh Trading VolumeLNTHLantheus4.5808 of 5 stars$86.90-2.0%$131.86+51.7%+39.1%$6.04B$1.50B14.46700Positive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$18.050.0%$22.00+21.9%N/A$6.04BN/A0.00N/APositive NewsGap UpBBIOBridgeBio Pharma4.5511 of 5 stars$31.76-0.3%$49.00+54.3%-6.2%$6.00B$9.30M-13.18400Short Interest ↓NUVLNuvalent2.6237 of 5 stars$83.40-2.7%$112.36+34.7%-9.6%$5.93BN/A-24.0340Positive News Related Companies and Tools Related Companies Roivant Sciences Alternatives Ascendis Pharma A/S Alternatives Revolution Medicines Alternatives Blueprint Medicines Alternatives Legend Biotech Alternatives Axsome Therapeutics Alternatives Lantheus Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives BridgeBio Pharma Alternatives Nuvalent Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TARS) was last updated on 2/17/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredTop Picks for Trump’s Pro-Crypto America10,000% Crypto Opportunities in 2025 27 of the brightest minds in crypto share exclusive intel… Crypto 101 Media | SponsoredHe called the top and bottom of Bitcoin nearly to the day … Here’s what he says is next.With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.